NEW YORK, July 22, 2026 – Danaher Corporation (NYSE: DHR) experienced its most severe single-day decline in over two decades on Tuesday, with shares tumbling 10.99% to close at $179.01. The sharp sell-off was triggered by the company's biotech division falling short of growth projections, prompting investors to reassess the stock's valuation multiples.
The market's reaction was a recalibration of valuation rather than a response to earnings disappointment. In fact, Danaher's quarterly revenue and adjusted earnings exceeded consensus estimates. Revenue rose 5.5% to $6.27 billion, surpassing FactSet's forecast of $6.11 billion, while adjusted earnings came in at $1.94 per share, ahead of the roughly $1.84 expected. Core revenue advanced 3%, compared to a 0.5% increase in the previous quarter.
However, the biotechnology segment, a key growth driver, posted core sales growth of just 2.5%, approximately 300 basis points below analysts' estimates. This weakness overshadowed stronger performances in other divisions: Life Sciences recorded a 5.5% increase, and Diagnostics advanced by 2% (or 5% excluding respiratory testing).
Danaher tightened its full-year core growth outlook to a range of 3%–4%, down from previous guidance. The midpoint for core growth dropped roughly 22%, while the midpoint for adjusted earnings per share edged higher to $8.525 from $8.45. As a result, the price-to-adjusted earnings multiple contracted from 23.8 times to 21.0 times, using range midpoints.
Chief Executive Rainer Blair attempted to reassure investors, stating, "Underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter." However, analysts remained cautious. Matt Larew of William Blair described bioprocessing as "surprisingly soft," while Guggenheim's Subbu Nambi noted that attention would remain on biotechnology growth in the second half.
The sell-off erased approximately $15.6 billion in market capitalization, based on the quarter's diluted share count. This is roughly 1.6 times the $9.9 billion Danaher paid for Masimo. Chief Financial Officer Matt Gugino noted that just over $100 million in bioprocessing revenue was deferred into 2027, but the market's reaction suggests broader concerns about the sustainability of growth and the reliability of forecasts.
Danaher increased its adjusted EPS outlook to a range of $8.45–$8.60, up from $8.35–$8.55, supported by the earlier-than-expected closing of the Masimo acquisition. Free cash flow grew 15.5% in the quarter, reaching $1.27 billion. For the third quarter, the company anticipates core growth of 2%–3%, factoring in a 2.5-point negative impact from respiratory testing. Excluding respiratory testing, growth is expected to be near 5%, with biotechnology projected to achieve mid-single-digit growth.
The stock had closed at $205.01 last Thursday before falling 12.7% by Tuesday. In contrast, the S&P 500 rose 0.9% that day, indicating Danaher's decline was largely company-specific. The next sector test is scheduled for Thursday, when Thermo Fisher Scientific (NYSE: TMO) will report its quarterly results. Investors will scrutinize its commentary on biopharma and research demand to determine if Danaher's softness is sector-wide.
Risks for Danaher include potential further delays in bioprocessing shipments, volatility in respiratory demand, and execution challenges related to the Masimo integration and acquisition-related debt. At 21 times guided adjusted earnings, the stock is less expensive than Monday's valuation, but this lower multiple must be justified by converting strong order growth into tangible sales.
